Morphini Sulfas Spinal Wzf (Morphine Sulfate)

Morphine sulfate works by binding to mu‑opioid receptors in the central nervous system. This binding inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and modulates pain pathways in the spinal cord and brain, leading to decreased perception of pain and increased pain tolerance.

The appropriate dose of Morphini Sulfas Spinal Wzf is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, route of administration, and individual clinical factors such as age, organ function, and concomitant medications. No fixed regimen is provided in public documentation.

Morphini Sulfas Spinal Wzf is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should only be used during pregnancy or lactation when the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Morphini Sulfas Spinal Wzf delivers morphine sulfate, a benchmark mu‑opioid receptor agonist. Compared with newer synthetic opioids, morphine has a well‑characterized efficacy and safety profile, but may have a higher incidence of certain side effects such as histamine‑mediated flushing. Choice of agent depends on clinical context, patient response, and regulatory considerations.

Store Morphini Sulfas Spinal Wzf below 25 °C in its original packaging. Protect the product from moisture, direct sunlight, and physical damage. Do not freeze the solution, and ensure the container remains sealed until use to maintain sterility.

The product is supplied as a sterile solution intended for injection. It may be administered epidurally, intrathecally, or intravenously by a qualified healthcare professional, following aseptic technique and appropriate dosing calculations as ordered by the prescriber.

The most serious risks include respiratory depression, severe hypotension, anaphylactic reactions, adrenal insufficiency, and seizures. Patients should be closely monitored for signs of respiratory compromise, cardiovascular instability, and any allergic manifestations, especially during initiation or dose escalation.

Morphini Sulfas Spinal Wzf should be avoided in individuals with known hypersensitivity to morphine or any component of the formulation, in patients with severe respiratory depression not adequately treated, and in those for whom opioid therapy is contraindicated, such as certain cases of acute asthma or paralytic ileus.